Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial

BACKGROUND: Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a dismal prognosis. Here, we report an analysis of CNS relapse for patients treated within the UK NCRI phase III R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone...

Descripción completa

Detalles Bibliográficos
Autores principales: Gleeson, M., Counsell, N., Cunningham, D., Chadwick, N., Lawrie, A., Hawkes, E. A., McMillan, A., Ardeshna, K. M., Jack, A., Smith, P., Mouncey, P., Pocock, C., Radford, J. A., Davies, J., Turner, D., Kruger, A., Johnson, P., Gambell, J., Linch, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834096/
https://www.ncbi.nlm.nih.gov/pubmed/28961838
http://dx.doi.org/10.1093/annonc/mdx353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834096/
https://www.ncbi.nlm.nih.gov/pubmed/28961838
http://dx.doi.org/10.1093/annonc/mdx353

Ejemplares similares